Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Matteo S. Carlino*, Georgina V. Long, Richard F. Kefford, Helen Rizos

*Corresponding author for this work

Research output: Contribution to journalReview article

29 Citations (Scopus)


BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.

Original languageEnglish
Pages (from-to)385-398
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Issue number3
Publication statusPublished - 1 Dec 2015


Cite this